Numab Announces Entry into a License Agreement With Intarcia for Anti-Inflammatory ND016
PFFFIKON, Switzerland--(BUSINESS WIRE)--Mar 5, 2019--Numab Therapeutics AG today announced that Intarcia Therapeutics Inc. has executed its option to in-license ND016, being develo…
